Cargando…
Health-care costs of losartan and candesartan in the primary treatment of hypertension
A recent study of two widely used angiotensin receptor blockers reported a reduced risk of cardiovascular events (−14.4%) when using candesartan compared with losartan in the primary treatment of hypertension. In addition to clinical benefits, costs associated with treatment strategies must be consi...
Autores principales: | Henriksson, M, Russell, D, Bodegard, J, Kjeldsen, S, Hasvold, P, Stålhammar, J, Levin, L-Å |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023072/ https://www.ncbi.nlm.nih.gov/pubmed/20376078 http://dx.doi.org/10.1038/jhh.2010.36 |
Ejemplares similares
-
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
por: Kjeldsen, S E, et al.
Publicado: (2010) -
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension
por: Granström, Ola, et al.
Publicado: (2012) -
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
por: Hasvold, L P, et al.
Publicado: (2014) -
Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients
por: Baroroh, Faridah, et al.
Publicado: (2019) -
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
por: Hasvold, Pål, et al.
Publicado: (2015)